Kisspeptin-10: Dosage, Benefits & Side Effects
By Peptide Assistant Editorial Team · · · 10 sources cited
Overview
Kisspeptin-10 is a truncated bioactive fragment of the kisspeptin family of peptides, which are the master regulators of reproductive hormone release. It activates the KISS1R receptor on GnRH neurons in the hypothalamus, triggering a potent surge of gonadotropin-releasing hormone and downstream LH/FSH secretion. It is studied for fertility, hypogonadism, and sexual health applications.
Mechanism of Action
Kisspeptin-10 binds to the KISS1R (GPR54) receptor on GnRH-expressing neurons in the hypothalamic arcuate and anteroventral periventricular nuclei. This activates phospholipase C signaling, increases intracellular calcium, and triggers pulsatile GnRH release from nerve terminals in the median eminence. GnRH then stimulates pituitary gonadotrophs to release LH and FSH. Kisspeptin is the most upstream activator of the reproductive axis — it sits above GnRH in the hormonal cascade. This is why it is put forward as a more physiological approach to HPG axis stimulation than direct GnRH or gonadotropin administration, though in a head-to-head infusion study GnRH raised LH about three times more than kisspeptin-10 did. Kisspeptin also has direct roles in sexual arousal — fMRI studies show it activates limbic brain regions associated with sexual processing and romantic bonding.
Kisspeptin-10 Benefits: What the Research Shows
- Dhillo et al. (2005) demonstrated kisspeptin-54 potently stimulated LH and FSH release in healthy men (Journal of Clinical Endocrinology & Metabolism)
- fMRI studies by Comninos et al. (2017) showed kisspeptin-54 enhanced brain processing of sexual and romantic stimuli in healthy men (Journal of Clinical Investigation)
- Research in women with hypothalamic amenorrhea showed that kisspeptin-54 infusion temporarily increased LH pulsatility, while chronic administration caused desensitization (Journal of Clinical Endocrinology & Metabolism, 2014)
- A phase 2 trial found that a single injection of kisspeptin-54 triggered oocyte maturation in 95% of 60 women at high risk of ovarian hyperstimulation syndrome, and none developed moderate, severe or critical OHSS
- An 11-hour kisspeptin-10 infusion raised LH and testosterone in five men with type 2 diabetes and mild hypogonadism, a proof-of-concept study (Clinical Endocrinology, 2013)
- Loss-of-function mutations in KISS1R cause hypogonadotropic hypogonadism, confirming kisspeptin's essential role in puberty and reproduction
Kisspeptin-10 Dosage
- Fertility/LH stimulation: research doses of kisspeptin-10 were 0.01 to 3 mcg/kg as an intravenous bolus, or infusions of 1.5 to 4 mcg/kg per hour
- HPG axis support: 100–500 mcg subcutaneous injection daily or every other day
- Some protocols use 200 mcg twice weekly for testosterone optimization
- Pulsatile administration (every 60–90 minutes) most closely mimics physiology but is impractical outside research settings
- Cycle: 4–8 weeks, assess hormonal response via blood work
- Morning dosing preferred to align with physiological GnRH pulsatility
- Can be combined with gonadorelin for multi-level HPG axis support
Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.
Kisspeptin-10 Side Effects & Safety
Known Side Effects
- Facial flushing (common, transient — related to rapid gonadotropin release)
- Headache (mild, typically during first few doses)
- Injection site discomfort
- Potential for ovarian hyperstimulation in women (clinical fertility context)
- Transient nausea
- Theoretical risk of HPG axis desensitization with continuous high-dose use
Safety Profile
Kisspeptin-10 has been given to small numbers of volunteers and patients in short physiology studies with no serious adverse events reported; the phase 2 trials were of kisspeptin-54, not kisspeptin-10. As the physiological master switch for reproduction, it produces effects consistent with HPG axis activation. The main safety consideration is avoiding continuous high-dose administration, which could paradoxically suppress the reproductive axis (similar to continuous GnRH). In women, there is a risk of ovarian hyperstimulation comparable to other fertility agents. Contraindicated in sex-hormone-dependent cancers (breast, prostate, ovarian), pregnancy, and in children (could trigger precocious puberty). Monitor LH, FSH, testosterone/estradiol, and gonadal function during use. Overall, well-tolerated at the research doses studied. FDA has placed kisspeptin-10 in category 2 of its compounding bulk substances list, over risks including immunogenicity.
What to Expect
Week 1: Possible facial flushing after injection. LH levels rise acutely. Subtle increases in libido may be noticed. Week 2–4: Testosterone levels begin rising (in men). Enhanced sexual responsiveness and arousal. Improved mood and energy associated with optimized sex hormones. Weeks 5–8: No study has given kisspeptin-10 for weeks at a time, and chronic kisspeptin administration causes desensitization. Libido, energy, and well-being improved. Fertility parameters (sperm count, motility) may improve in men with prior suppression. Women may notice improved cycle regularity. Effects are reversible upon discontinuation.
Common Stacks
Gonadorelin Acetate
Kisspeptin activates GnRH neurons while gonadorelin directly stimulates the pituitary — sequential multi-level HPG axis activation
PT-141
Kisspeptin enhances sexual brain processing while PT-141 directly activates melanocortin-mediated sexual arousal — complementary pro-sexual effects
Storage & Handling
Store lyophilized at -20°C for optimal stability (up to 12 months) or 2–8°C for up to 6 months. Reconstitute with bacteriostatic water. Refrigerate reconstituted solution and use within 2–3 weeks. Kisspeptin-10 is a small peptide and moderately stable but should be protected from heat and light.
Pricing & Available Variants
Prices sourced from peptides.gg marketplace. Prices may vary.
References
- George JT, Veldhuis JD, Roseweir AK, et al. Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. J Clin Endocrinol Metab. 2011.
- Dhillo WS, Chaudhri OB, Patterson M, et al. Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. J Clin Endocrinol Metab. 2005.
- Comninos AN, Wall MB, Demetriou L, et al. Kisspeptin modulates sexual and emotional brain processing in humans. J Clin Invest. 2017.
- Jayasena CN, Abbara A, Veldhuis JD, et al. Increasing LH pulsatility in women with hypothalamic amenorrhoea using intravenous infusion of Kisspeptin-54. J Clin Endocrinol Metab. 2014.
- Abbara A, Jayasena CN, Christopoulos G, et al. Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy. J Clin Endocrinol Metab. 2015.
- George JT, Veldhuis JD, Tena-Sempere M, et al. Exploring the pathophysiology of hypogonadism in men with type 2 diabetes: kisspeptin-10 stimulates serum testosterone and LH secretion in men with type 2 diabetes and mild biochemical hypogonadism. Clin Endocrinol (Oxf). 2013.
- Seminara SB, Messager S, Chatzidaki EE, et al. The GPR54 gene as a regulator of puberty. N Engl J Med. 2003.
- Jayasena CN, Abbara A, Narayanaswamy S, et al. Direct comparison of the effects of intravenous kisspeptin-10, kisspeptin-54 and GnRH on gonadotrophin secretion in healthy men. Hum Reprod. 2015.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration. 2026.
- The Prohibited List 2026, section S2.2.1 Testosterone-stimulating peptides in males. World Anti-Doping Agency. 2026.
Related Peptides
Track Kisspeptin-10 in Your Protocol
Log your Kisspeptin-10 doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.
Start Tracking Free